NCT00763451 - GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Biotech Hunter

Enrollment

484

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Lixisenatide (AVE0010)

Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

DRUG

Placebo

Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

DEVICE

Pen auto-injector

DRUG

Metformin

Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.

Trial Locations (15)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Bogotá

Sanofi-Aventis Administrative Office, Tallinn

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Vilnius

Sanofi-Aventis Administrative Office, Kuala Lumpur

Sanofi-Aventis Administrative Office, México

Sanofi-Aventis Administrative Office, Makati City

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Bucharest

Sanofi-Aventis Administrative Office, Brastislava

Sanofi-Aventis Administrative Office, Kiev